ResearcherLeukogene Therapeutics, Inc.Active in the last 2 years
Nathan G. Dolloff
Matched on ORCID iD 0000-0002-9181-2180; OpenAlex author ID A5008093569; NIH RePORTER profile ID 10840376. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 8
2021: 1 grant · 2022: none · 2023: 1 paper · 2024: 1 paper, 1 grant · 2025: 1 paper
Papers 3
- Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Last author DOI 10.3390/biom15050645↗
- A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Last author DOI 10.3390/antib13040101↗
- Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis. Co-author DOI 10.3233/cbm-220044↗
Grants 2
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John P O'Bryan · 3 shared papers, 2023–2025 · strength 0.59
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Reeder M. Robinson · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Benjamin N. Christopher · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- G. Aaron Hobbs · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Julie B. Siegel · 2 shared papers, 2023–2024 · strength 0.35
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Nancy Klauber‐DeMore · 2 shared papers, 2023–2024 · strength 0.35
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Denis C. Guttridge D · 1 shared paper, 2025 · strength 0.24
- Rachel A. Burge · 1 shared paper, 2024 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.